


Emoje

1631

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENTDocket No.  
PB0176

In Re Application Of: Yizhong Gu, et al.

Serial No.  
10/060,990Filing Date  
30 January 2002Examiner  
Cheyne D. LyGroup Art Unit  
1631

Invention: Human RalGDS-Like Protein 3

TO THE COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

## Statement Under 37 CFR 1.97(e)(1)

- ☒ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

## Statement Under 37 CFR 1.97(e)(2)

- ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

  
Signature

Dated: March 12, 2004

Yonggang Ji  
Amersham Biosciences Corp  
Patent Department  
800 Centennial Avenue  
Piscataway, New Jersey 08855

(732) 980-2875

Reg. No.: 53,073

## Certificate of Mailing by First Class Mail


I certify that this document is being deposited on  
March 12, 2004 with the U.S. Postal Service as first  
class mail under 37 C.F.R. 1.8 and is addressed to the  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450.

  
Signature of Person Mailing Correspondence

Melissa Leck

Typed or Printed Name of Person Mailing Correspondence

cc:



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/060,990
Filing Date	30 January 2002
First Named Inventor	Yizhong Gu
Art Unit	1631
Examiner Name	Cheyne D. Ly
Attorney Docket Number	PB0176

Sheet	1	of	1
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	SHAO, Haipeng, et al. "A novel RalGEF-like protein, RGL3, as a candidate effector for Rit and Ras" Journal of Biological Chemistry, volume 275, number 35, 1 September 2000 pages 26914-26924	
	C2	EHRHARDT, Gotz, R., A., et al. "A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth" Oncogene, volume 20, number 2, 11 January 2001, pages 188-197	
	C3	Database EMBL Genbank 'Online! 24 May 2000 "Homo sapiens cDNA, ..." Database accession no. AW847439.1	
	C4	Database EMBL Genbank 'Online! 24 September 2001 "Homo Sapiens RalGEF-like protein 3" Database accession no. BC014426	
	C5	Database EMBL Genbank 'Online! 31 October 2001 "Homo sapiens cDNA..., highly similar to Mus musculus RalGDS-like protein 3 mRNA" Database accession no. AK057147	
	C6	Database EMBL Genbank 'Online! 16 January 2002 "Human novel cytokine ..." Database accession no. AAS59848	
	C7	Database EMBL Genbank 'Online! 16 June 2001 "Homo Sapiens cDNA, ..." Database accession no. BI009484	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.